Bristol-myers Squibb Compnay

Viiv Healthcare UK Limited

Bristol-myers Squibb Holdings Ireland

Jeffrey Lee Romine

Denis R St Laurent

Nicholas A Meanwell

Lawrence B Snyder

Omar D Lopez

Makonen Belema

Van N Nguyen

Jason T Goodrich

Fukang Yang

Andrew Charles Good

Lawrence G Hamann

Rico Lavoie

Edward H Ruediger

David R Langley

Alain Martel

Carol Bachand

Daniel H Deon

Clint A James

Gan Wang

Scott W Martin

Piyasena Hewawasam

John A Bender

Michael H Serrano-Wu

John F Kadow

John E Starrett, Jr

Yuping Qiu

Valentin K Gribkoff

Ramesh Kakarla

Zhong Yang

Ningning Xu

Xuejie Yang

Jayne Kapur

Paul Michael Scola

Tao Wang

Milind Deshpande

Zhongxing Zhang

B Narasimhulu Naidu

Kap-Sun Yeung

Manoj Patel

Peter W Glunz

Brent D Douty

Darren Whitehouse

Min Gao

Guo Li

Michael J Smith

Qi Chen

Julie A Lemm

Donald R O'Boyle

Richard Colonno

Brent Dale Douty

John A Easter

Bao-Ning Su

Denis R STLAURENT

Belema Makonen

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various pp diseases, including cancer and infectious diseases. (I) 

Substituted isoquionline derivatives as immunomudulators

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

The disclosure generally relates to compounds of formula I, II, III and IV, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds. 

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.

Growing community of inventors

Meriden, CT, United States of America

Jeffrey Lee Romine